Eugene Johnston - Mangoceuticals, Common Chief Officer
| MGRX Stock | 2.55 0.05 2.00% |
Executive
Eugene Johnston is Chief Officer of Mangoceuticals, Common Stock
| Age | 60 |
| Address | 15110 North Dallas Parkway, Dallas, TX, United States, 75248 |
| Phone | (214) 242-9619 |
| Web | https://www.mangoceuticals.com |
Eugene Johnston Latest Insider Activity
Tracking and analyzing the buying and selling activities of Eugene Johnston against Mangoceuticals, Common stock is an integral part of due diligence when investing in Mangoceuticals, Common. Eugene Johnston insider activity provides valuable insight into whether Mangoceuticals, Common is net buyers or sellers over its current business cycle. Note, Mangoceuticals, Common insiders must abide by specific rules, including filing SEC forms every time they buy or sell Mangoceuticals, Common'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Eugene Johnston over two weeks ago Acquisition by Eugene Johnston of 25000 shares of Mangoceuticals, Common subject to Rule 16b-3 |
Mangoceuticals, Common Management Efficiency
The company has return on total asset (ROA) of (0.5751) % which means that it has lost $0.5751 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0844) %, meaning that it created substantial loss on money invested by shareholders. Mangoceuticals, Common's management efficiency ratios could be used to measure how well Mangoceuticals, Common manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to -8.33 in 2024. Return On Capital Employed is likely to rise to -10.43 in 2024. At this time, Mangoceuticals, Common's Net Tangible Assets are fairly stable compared to the past year. Fixed Asset Turnover is likely to rise to 3.57 in 2024, whereas Total Assets are likely to drop slightly above 761.4 K in 2024.Similar Executives
| Found 13 records | EXECUTIVE Age | ||
| J Koffenberger | Bullfrog AI Holdings, | N/A | |
| Anand Kumar | Healthcare Triangle | 50 | |
| X DPHIL | Bullfrog AI Holdings, | N/A | |
| Dane Saglio | Bullfrog AI Holdings, | 66 | |
| Michael Campana | Healthcare Triangle | N/A | |
| William Hirschman | Bullfrog AI Holdings, | N/A | |
| Martin FCA | FOXO Technologies | 67 | |
| FACP FACR | Bullfrog AI Holdings, | 66 | |
| Cetin Savkli | Bullfrog AI Holdings, | N/A | |
| Yew CPA | EUDA Health Holdings | 56 | |
| Dr DPHIL | Bullfrog AI Holdings, | N/A | |
| Abhay Borwankar | Healthcare Triangle | N/A | |
| Damian David | Healthcare Triangle | N/A | |
Management Performance
| Return On Equity | -1.08 | ||||
| Return On Asset | -0.58 |
Mangoceuticals, Common Leadership Team
Elected by the shareholders, the Mangoceuticals, Common's board of directors comprises two types of representatives: Mangoceuticals, Common inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Mangoceuticals,. The board's role is to monitor Mangoceuticals, Common's management team and ensure that shareholders' interests are well served. Mangoceuticals, Common's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Mangoceuticals, Common's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Eugene Johnston, Chief Officer | ||
| Amanda Hammer, Chief Officer | ||
| Jonathan Arango, Secretary President | ||
| Jacob Cohen, CEO CoFounder |
Mangoceuticals, Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Mangoceuticals, Common a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.08 | ||||
| Return On Asset | -0.58 | ||||
| Operating Margin | (13.05) % | ||||
| Current Valuation | 6.41 M | ||||
| Shares Outstanding | 2.49 M | ||||
| Shares Owned By Insiders | 37.45 % | ||||
| Shares Owned By Institutions | 4.69 % | ||||
| Number Of Shares Shorted | 152.88 K | ||||
| Price To Book | 0.46 X | ||||
| Price To Sales | 7.26 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Mangoceuticals, Stock Analysis
When running Mangoceuticals, Common's price analysis, check to measure Mangoceuticals, Common's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mangoceuticals, Common is operating at the current time. Most of Mangoceuticals, Common's value examination focuses on studying past and present price action to predict the probability of Mangoceuticals, Common's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mangoceuticals, Common's price. Additionally, you may evaluate how the addition of Mangoceuticals, Common to your portfolios can decrease your overall portfolio volatility.